Comera Life Sciences Holdings, Inc.: Nasdaq/NYSE listing notice — Comera Life Sciences receives Nasdaq delisting notice for failing MVLS standard

Comera Life Sciences Holdings, Inc.

Received Nasdaq determination letter on May 18, 2023 for non-compliance with $35M MVLS minimum.
Grace period ended May 17, 2023; stock had not achieved $35M MVLS for 10 consecutive days.
Must request hearing by May 25, 2023 to appeal; otherwise delisting on May 30, 2023.
Company intends to request a hearing; trading will continue until Panel decision.
If delisted, common stock expected to trade on OTC Markets Group.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Comera Life Sciences Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

May 18, 2023, Comera Life Sciences Holdings, Inc. (the “Company”) received a determination letter (the “Letter”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has not regained compliance with the Market Value of Listed Securities (“MVLS”) Standard, since the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MLVS Rule”) and had not been at least $35 million for a minimum of 10 co

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-023269

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.